financetom
Business
financetom
/
Business
/
American International Group Q2 Adjusted Income, Net Investment Income Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
American International Group Q2 Adjusted Income, Net Investment Income Rise
Jul 31, 2024 2:10 PM

04:36 PM EDT, 07/31/2024 (MT Newswires) -- American International Group ( AIG ) reported Q2 adjusted income late Wednesday of $1.16 per diluted share, up from $1.06 last year.

Analysts polled by Capital IQ expected $1.30.

Net investment income for the quarter ended June 30 was $990 million, up from $837 million a year earlier. Analysts surveyed by Capital IQ expected $808.5 million.

The company's board also kept its quarterly dividend at $0.40 per share, payable on Sept. 30 to shareholders of record on Sept. 16.

AIG shares were down 1% in after-hours activity.

Price: 78.12, Change: -1.11, Percent Change: -1.40

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wepoint, a new North American AI leader: 1,500 experts by 2030 following the strategic merger with Logient nventive
Wepoint, a new North American AI leader: 1,500 experts by 2030 following the strategic merger with Logient nventive
Sep 30, 2025
MONTREAL, Sept. 30, 2025 /PRNewswire/ - The North American digital landscape welcomes Wepoint, a new key player in artificial intelligence and digital transformation. The creation of this entity stems from the ambition of the French international group Onepoint to expand on the continent, made possible by the strategic merger with Quebec-based Logient nventive. Present in Montreal for two decades, Onepoint...
BRIEF-NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
BRIEF-NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Sep 30, 2025
Sept 30 (Reuters) - Kadimastem Ltd: * NLS PHARMACEUTICS SHAREHOLDERS APPROVE MERGER WITH KADIMASTEM AND RELATED PROPOSALS AT EXTRAORDINARY GENERAL MEETING Source text: Further company coverage: ...
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Sep 30, 2025
Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH, Sept. 30, 2025 /PRNewswire/ --NLS Pharmaceutics Ltd. (NLS), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and Kadimastem Ltd. (TASE: KDST) (Kadimastem), an advanced clinical-stage cell therapy company developing...
BRIEF-UK's CMA Announces Merger Investigation Into S&P Global Market Intelligence Inc. / ORBCOMM AIS Merger
BRIEF-UK's CMA Announces Merger Investigation Into S&P Global Market Intelligence Inc. / ORBCOMM AIS Merger
Sep 30, 2025
Sept 30 (Reuters) - UK's CMA: * COMPETITION AND MKTS - MERGER UPDATE: S&P / ORBCOMM * UK'S CMA: START OF CMA MERGER INVESTIGATION: S&P GLOBAL MARKET INTELLIGENCE INC. / ORBCOMM AIS LLC * UK'S CMA: LAUNCH OF MERGER INQUIRY INTO S&P GLOBAL MARKET INTELLIGENCE INC. / ORBCOMM AIS LLC DEAL; HAS A DEADLINE OF 25 NOV FOR PHASE 1...
Copyright 2023-2026 - www.financetom.com All Rights Reserved